Therapy with CD7 monoclonal antibody TH‐69 is highly effective for xenografted human T‐cell ALL

Authors:

Abstract
Human T‐cell acute lymphocytic leukaemia (ALL) was established in athymic nude or severe combined immunodeficient (SCID) mice by injecting CEM or MOLT‐16 cells. When nude mice bearing approx. 2 g of tumour were treated with a single injection of CD7 antibody TH‐69, 82.6% reached complete remission within 10 d whereas 13.0% showed partial remission. Similarly, in SCID mice with advanced disease a significant prolongation of survival was seen. The therapeutic effects were dependent upon dose and affinity of the antibody. TH‐69 is a high‐affinity antibody (7.6 × 109 M−1) that rapidly induced modulation during treatment. The Fc‐portion of the antibody was required for effective tumour cell killing. Complement deposition was found on tumour sections after TH‐69 treatment and in part may account for tumour destruction. There was no evidence for antibody‐dependent cellular cytotoxicity (ADCC). The kinetics of tumour disappearance suggested the initiation of a programmed cell death (PCD), despite the lack of significant DNA fragmentation. Unmodified high‐affinity antibodies to the T‐cell antigen CD7 have potential for T‐cell ALL therapy.